Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
WGS vs OPK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
OPK Captures Overall Composite Edge (38.6 SELL vs 49.5 HOLD), While WGS Leads 5–1 on Growth & Valuation Pillars
OPK Overall Winner
6-Pillar Tally: WGS 5 – 1 OPK
Matrix Metrics: WGS 5 – 5 OPK
As of Nov 16, 2026, Opko Health Inc. (OPK) captures the overall head-to-head institutional edge over GeneDx Holdings Corp. (WGS) on higher Unified Composite conviction (38.6/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale), while WGS wins 5–1 across the 6-pillar growth and valuation breakdown. WGS trades at $51.02 (40.6x Forward P/E, -13.7% operating margin) versus OPK at $1.62 (53.8x Forward P/E, -27.8% operating margin).
- Composite vs. Pillar Nuance: While WGS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. OPK 38.6/100 SELL), OPK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-27.8% vs. -13.7% operating margin) and revenue trajectory (+15.9% vs. +5.4% YoY).
- Technical & Structure Timing Caution: WGS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8); meanwhile OPK trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About WGS vs OPK
WGS
GeneDx Holdings Corp. Class A Common Stock
$51.02
-2.58% 1D
Market Cap
$1.6B
TTM Revenue
$461M
Forward P/E
40.6x
Beta / 30D Vol
1.74β · 111% Vol
Unified Composite Score
49.5
HOLD
Tech 33.0
Fund 53.0
Flow 70.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
OPK
Head-to-Head Winner
Opko Health Inc.
$1.62
-3.57% 1D
Market Cap
$1.2B
TTM Revenue
$654M
Forward P/E
53.8x
Beta / 30D Vol
0.77β · 31% Vol
Unified Composite Score
38.6
SELL
Tech 30.0
Fund 43.0
Flow 65.0
Mom 36.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (WGS 5 – 1 OPK)
1. Valuation Multiples
WGS
Forward P/E
40.6x
53.8x
Trailing P/E
38.8x
53.8x
PEG Ratio
N/M
N/M
EV / Revenue
3.7x
2.1x
2. Growth & Scale
OPK
Revenue Growth (YoY)
+5.4%
+15.9%
Earnings Growth (YoY)
+0.0%
-12.6%
TTM Revenue (USD)
$461M
$654M
Market Cap
$1.6B
$1.2B
3. Profitability & Quality
WGS
Gross Margin
68.8%
19.6%
Operating Margin
-13.7%
-27.8%
Net Profit Margin
-24.1%
-22.6%
Return on Equity (ROE)
-41.4%
-8.9%
4. Balance Sheet & Cash Flow
WGS
Cash Generation (TTM)
-$101M
-$136M
Cash Flow Margin
-22.0%
-20.8%
Net Cash / Leverage
$119M Net Debt (0.88x D/E)
$125M Net Debt (0.46x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
WGS
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
102.3% (21st %ile)
58.9% (3rd %ile)
Put/Call OI Skew
7.82x (Put-Skewed)
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
WGS
OpEx & R&D Intensity
82.5% of Rev ($380M)
47.4% of Rev ($310M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: WGS (5) vs OPK (5)| Institutional Metric | WGS | OPK | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.6B | $1.2B | WGS | |
| Trailing P/E Ratio | 38.8x | 53.8x | WGS | |
| Forward P/E Ratio | 40.6x | 53.8x | WGS | |
| Revenue Growth (YoY) | +5.4% | +15.9% | OPK | |
| Operating Margin (TTM) | -13.7% | -27.8% | WGS | |
| Net Profit Margin | -24.1% | -22.6% | OPK | |
| Return on Equity (ROE) | -41.4% | -8.9% | OPK | |
| 52-Week Range Position | 14% ($32–$171) | 73% ($1–$2) | OPK | |
| Beta / 30D Volatility | 1.74β · 111% Vol | 0.77β · 31% Vol | OPK | |
| Unified Institutional Score | 49.5 / 100 (HOLD) | 38.6 / 100 (SELL) | WGS | |
| Trailing 12M Revenue (USD) | $461M | $654M | Scale | |
| Gross Profit Margin (TTM) | 68.8% | 19.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.7x EV/Rev | N/M PEG · 2.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$101M ($119M Net Debt (0.88x D/E)) | -$136M ($125M Net Debt (0.46x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
OPK +25.67 pp
3M Horizon
OPK +52.29 pp
6M Horizon
OPK +23.85 pp
1Y Horizon
OPK +87.42 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | WGS Revenue | OPK Revenue | WGS Op. Margin | OPK Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $990M | N/A | -17.3% | OPK |
| FY2019 | $200M | $900M | -15.5% | -30.4% | WGS |
| FY2020 | $180M | $1.44B | -134.9% | 4.0% | OPK |
| FY2021 | $210M | $1.77B | -210.3% | 1.1% | OPK |
| FY2022 | $230M | $1.00B | -284.5% | -22.5% | OPK |
| FY2023 | $200M | $860M | -89.2% | -18.2% | OPK |
| FY2024 | $310M | $710M | -7.6% | -21.3% | WGS |
| FY2025 | $430M | $610M | -3.1% | -19.3% | WGS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
WGS
BREAKDOWN
Current IV
102.3%
IV Percentile
21st %ile
Put/Call OI Skew
7.82x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact WGS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
OPK
CONSOLIDATION
Current IV
58.9%
IV Percentile
3rd %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact OPK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
WGS Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
82.5% of Rev ($380M)
90D Engineering Disclosures
0 Published
OPK Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
47.4% of Rev ($310M)
90D Engineering Disclosures
0 Published
Investor FAQ WGS vs OPK Key Questions & Quantitative Answers
As of Nov 16, 2026, Opko Health Inc. (OPK) captures the overall head-to-head institutional edge over GeneDx Holdings Corp. (WGS) on higher Unified Composite conviction (38.6/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale), while WGS wins 5–1 across the 6-pillar growth and valuation breakdown. WGS trades at $51.02 (40.6x Forward P/E, -13.7% operating margin) versus OPK at $1.62 (53.8x Forward P/E, -27.8% operating margin). Composite vs. Pillar Nuance: While WGS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. OPK 38.6/100 SELL), OPK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-27.8% vs. -13.7% operating margin) and revenue trajectory (+15.9% vs. +5.4% YoY). Technical & Structure Timing Caution: WGS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8); meanwhile OPK trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OPK leads the Growth & Scale pillar: WGS posts +5.4% YoY revenue growth and +0.0% YoY earnings growth on $461M TTM revenue (68.8% gross margin, -13.7% operating margin), compared with OPK at +15.9% YoY revenue growth and -12.6% YoY earnings growth on $654M TTM revenue (19.6% gross margin, -27.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), WGS cumulative revenue shifted +115.0% while OPK shifted -38.4%. In operating R&D and SG&A reinvestment, WGS deploys 82.5% of Rev ($380M) (0 90-day corporate R&D disclosures) versus 47.4% of Rev ($310M) (0 disclosures) for OPK.
WGS screens cheaper on headline valuation multiples. WGS trades at 40.6x Forward P/E, 38.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (-22.0% FCF margin), whereas OPK trades at 53.8x Forward P/E, 53.8x Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-20.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WGS (-41.4% ROE) versus OPK (-8.9% ROE) capital efficiency.
In options market volatility and institutional positioning, WGS carries 102.3% implied volatility (21st %ile, Compressed (<25th %ile)), a 7.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 111% Vol realized risk). By comparison, OPK carries 58.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 31% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
OPK vs WGS · Reverse Pair
WGS vs SEZL
· Sector Peer
WGS vs GRAL
· Sector Peer
WGS vs NTRA
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking